FLUIDDA

FLUIDDA has pioneered Functional Respiratory Imaging (FRI), a proprietary platform that fuses medical imaging, computational fluid dynamics, and artificial intelligence to quantify and visualize lung function in unprecedented detail. Its business model is dual-pronged: offering CRO services to accelerate and de-risk respiratory drug and device development for pharma/biotech, and providing clinical decision support tools (e.g., Broncholab®) for pulmonologists and radiologists. The company was acquired by Banook, a global clinical trial services leader, in late 2025, significantly enhancing its global reach and operational scale to drive adoption of its technology in both clinical research and personalized patient care.

Functional Respiratory Imaging (FRI): A proprietary platform combining High-Resolution CT (HRCT) scans, AI-powered 3D segmentation, and Computational Fluid Dynamics (CFD) simulations to create patient-specific, quantitative models of lung function and airflow.

FLUIDDA is a recognized leader in functional lung imaging analytics, but faces competition from other medical imaging analysis companies (e.g., VIDA Diagnostics) and broader digital health platforms developing respiratory biomarkers. Its unique integration of CFD with clinical imaging and its new position within a global CRO provide a distinct competitive moat.